This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum

Early Bird Price ends in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Marina Bay Sands Convention Center
April 24—25, 2024 | SingaporeApril 29—30, 2024 | Virtual

ImmuneOnco Biopharmaceuticals Inc

Profile

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a joint stock company founded in the Zhangjiang High Tech Park, China (Shanghai) Pilot Free Trade Zone in June, 2015. We are a science-driven biotechnology company dedicated to the development of next-generation immuno-oncology therapies. We stand out as one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. Currently approved immunotherapies primarily focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address significant unmet medical needs of cancer patients. We have 7 ongoing clinical programs since our company inception.